Skip to main content
Fig. 4 | BMC Pulmonary Medicine

Fig. 4

From: Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment

Fig. 4

Correlation of CTSF expression with infiltration levels of immune cells and immunomodulators in NSCLC. A Landscape of infiltrating immune cells in cancerous and healthy biopsies for TCGA-LUAD and TCGA-LUSC cohorts, respectively; B EPIC scores of immune infiltrating cells between normal lung tissues and LUAD or LUSC tissues, respectively; C association of CTSF copy numbers with immune cell infiltration levels in LUAD (above) and LUSC (below) cohorts, respectively; D, E Correlation between CTSF expression and immune cells in LUAD (D) and LUSC (E), respectively; F Heatmap of CTSF-related immunomodulators in LUAD and LUSC, respectively; G association of CTSF-related immunostimulators (TMEM173, IL6R, ICOS, and ENTPD1) and CTSF-related immunoinhibitor (CTLA4) with favorable prognosis of LUAD patients; H Association of CTSF-related immunostimulators (TNFSF13, CD276, IL6, CD27, PVR, TNFSF9, TMIGD2) and CTSF-related immunoinhibitor (LAG3) with poor prognosis of LUAD patients; (I) Relationship of CTSF-related immunostimulators CD27 and TNFRSF17 (also BCMA) with good prognosis of LUSC patients

Back to article page